Hematology & Oncology Doctors in Bridgewater, NJ Accepting Medicare

3 Hematology & Oncology doctors found. Showing 1 - 3

Steven Eugene Young, M.D. Internal Medicine - Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 1200 Us Highway 22 3rd Fl, Bridgewater, NJ 08807 Phone: 732-390-7750    Fax: 908-530-2929

Jonathan Z Rosenbluth, MD Internal Medicine - Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 1200 Us Highway 22 Ste 3, Bridgewater, NJ 08807 Phone: 732-390-7750    Fax: 908-530-2929

Beiqing Pan, M.D. Internal Medicine - Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 1200 Us Highway 22 Ste 3, Bridgewater, NJ 08807 Phone: 732-390-7750    Fax: 908-530-2929

News Archive

Researchers highlight how BSI infecting pathogens become more resilient

A recently published special issue of Virulence, "Bloodstream Infections", focuses on the resilience of bloodstream infections (BSI) and is endorsed by the European Study Group for Infections in Compromised Hosts of the European Society of Clinical Microbiology and Infectious Diseases.

What you see affects what you hear

Understanding what a friend is saying in the hubbub of a noisy party can present a challenge - unless you can see the friend's face.

Euroscience calls for support for convicted health workers in Libya

Euroscience calls on other academic and scientific organisations to protest at the conviction of six foreign medical workers, by a Libyan court of conspiring to deliberately inject 426 Libyan children with HIV virus.

Bacteria and fungi may protect against asthma in rural children: Study

Children who grow up on farms are less likely to suffer from asthma than other rural children. An international team of researchers including Dr. Markus Ege and Professor Erika von Mutius at Ludwig-Maximilians-Universitaet has published a large-scale study that now indicates that this may be due to differences in the spectrum of microbes the two groups are likely to encounter.

IDM Pharma plans to amend NDA for Mifamurtide (L-MTP-PE) for the treatment of osteosarcoma

IDM Pharma, Inc. has announced that it has recently met with the U.S. Food and Drug Administration (FDA) and informed the FDA that the Company intends to take immediate action to supplement the data in its current New Drug Application (NDA) for mifamurtide (L-MTP-PE), formerly known as Junovan, which is being reviewed for the treatment of children and adolescents with non-metastatic osteosarcoma.

Read more Medical News

› Verified 1 days ago